CONELIS - Key Persons
Job Titles:
- Member of the Conelis Honorary
- Veterinarian, Non - Clinical Development
Job Titles:
- Member of the Conelis Honorary
- Regulatrory Affairs
Job Titles:
- Member of the Conelis Honorary
Dr. Anke Maassen has a broad research and industry background (In total about 30 years in academic research, IVD industries and consulting).
She has over 20 years of experience in 4 IVD companies as Director of R&D and Production. Her main area of responsibility included implementing of quality management systems and ensuring full compliance with all rules, regulations, legal and other requirements in production and R&D.
Qualifications
Education:
Dr. Astrid Schott has over 25 years of experience in clinical medicine and drug development.
She graduated as MD from the University of Kiel, Germany, is board certified in General Medicine and joined the pharmaceutical Industry in 1996, working for Schering AG, their daughter company Berlex Inc. in the US and Bayer Schering Pharma, then joined Pharmion and 2007 started her own consulting business.
Her positive track record consists of several successful European Marketing Authorizations in the field of Oncology. She designed the global clinical development plans (phase I-III) of several novel products in the field of oncology, immunology and infectiology. She has experience with both positive as also negative proof of concept leading to expansion or canceling of projects and successfully initiated and used biomarker programs.
She has broad global management experience, including restructuring, change management and integration.
Astrid is founder of CONELIS e.v. and was member of the board from 2009 to 2014.
Qualifications
Broad clinical and industry background (>25 years clinical medicine, academic research, drug development in Pharma and Biotech)
Education:
Board certified in General Medicine, Dr. med.
Experience:
Consultant and Interim Manager for Global Clinical Drug Development
Senior Director International Clinical Development Pharmion, Windsor, UK
Executive Director Bayer Schering Pharma AG
Dr. Christian Hucke is a pro-active and hands-on senior manager with 20 years of experience in global Clinical Development and Operations. He founded Christian Hucke Pharma Consulting and Services in 2016. Prior to becoming a consultant he held project management and line management positions in CROs, Pharma and Biotech companies.
As a project manager Dr. Christian Hucke has led multi-disciplinary matrix teams with responsibility for activities in the EU, USA, CEE, LATAM and APAC. As a line manager he served as Head of Clinical Operations in a Biotech company and as Chief Operating Officer in a CRO.
Dr. Christian Hucke has managed projects and clinical studies from R2D transition to phase III in various indications, among them oncology and hematology (CRC, HL, NHL), CNS (ischemic stroke, pain, psycological disorders), ophtalmology (uveitis) and infections (SARS-CoV-2). Projects included personalized medicine approaches, technology platforms ranged from small molecules to antibodies, peptides, and mRNA.
The track record of Dr. Christian Hucke further includes the participation in authority meetings and inspections (e.g., FDA, PEI, MHRA, ANSM; German local authorities), leading task forces, Quality Management in GCP/GCLP, establishment and execution of Risk Management and oversight concepts, and corporate development projects.
Qualifications
Education: Biologist, PhD
Areas of Expertise: Interim Management, Project Management, Clinical Operations, Quality Risk Management
Job Titles:
- Co - Founder and Managing Partner of Lycalis Sprl
Dr. Christian Wolf is a co-founder and managing partner of Lycalis sprl, a Belgian limited company established in 2009.
Over the past 20 years, Dr. Wolf held project and line management positions at global pharmaceutical companies. In these roles, he led numerous early and late-stage clinical development programmes in CNS indications to decision points. He has been a principal investigator or member of steering committees for many clinical studies in the field of neurology covering a range of technological platforms including small molecules, therapeutic proteins, antibodies, and biosimilars.
Dr. Wolf's expertise comprises a range of CNS indications with most recent exposure to multiple sclerosis, epilepsy, and cognitive disorders. Additional activities in ischemic stroke, bipolar disorders, and movement disorders complement his profile as a CNS "all-rounder".
Dr. Wolf managed MDs, scientists, and other development professionals in Europe and the US. Responsibilities included activities for blockbuster drugs such as Keppra® or Betaferon®. His track record includes also interaction with major regulatory agencies (EMA, FDA, BfArM, MHRA) and collaborative projects with North American and Japanese corporations.
As a consultant, Dr. Wolf has been retained by European and non-European companies as well as by authorities such as the European Commission's DG for Research and Innovation. Clients included top-5, mid-sized, start-up, and VC entities.
Job Titles:
- Clinical Development, R & D Strategies
- Founder, CEO and Senior Consultant of Lampe & Company
Hans Hendriks, Ph.D., held positions in Cell Biology and Immunology at the Vrije Universiteit (Amsterdam, The Netherlands). After 17 years he joined the New Drug Development Office (now part of INC Research), Europe's foremost oncology Contract Research Organisation (Amsterdam, The Netherlands), gaining 12 years experience leading international drug discovery and development collaborations. In addition, he served in various drug development and drug evaluation committees of the EORTC, Cancer Research UK and US National Cancer Institute, and held for 8 years a position in the Executive Board of the EORTC Biological Therapeutics Development Group.
He established Hendriks Pharmaceutical Consulting January 2000, an independent consultancy company providing services to SMEs and biotechs in Oncology R&D. He is co-founder of the Cancer Drug Development Forum (CDDF, formerly knowns as Biot
He was successful in bringing the telomere targeting agent KML001 from early stage preclinical research to Phase I clinical studies (CCR 2008;14:4593-602) and is co-inventor of a US patent application (2009).
Qualifications
Education:
Hendriks et al, Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds inititative, British Journal of Cancer 2017;117:195-202
Job Titles:
- Member of the Conelis Honorary
- Clinical Development
Job Titles:
- Cardiac Safety Expert / CEO Richmond Pharmacology / London
- Expert
- Member of ACCP
Dr Täubel is an expert in clinical pharmacology with a special interest in cardiac safety assessments. During Dr Täubel's career he has been involved with over 400 clinical pharmacology studies. These have included trials in healthy volunteers including adolescents and also a wide range of patient poulations suffering from, for example, heart failure, hypertension, diabetes, asthma, multiple sclerosis, schizophrenia, atopic dermatitis and neuropathic pain. Current studies include work with patients with cardiomyopathies, neuropathies, congenital hyperinsulinism and erectile dysfunction. Dr Täubel's current research focus is on cardiac safety assessments and ethnic comparison studies. Dr Täubel currently is the CEO of Richmond Pharmacology which he co-founded with two medical colleagues in 2001 at St George's University Hospital in London. He is one of two MHRA accredited principal investigators for Richmond Pharmacology's 66 beds Phase I Unit.
Dr Täubel is a member of ACCP, JSCPT, AHPPI, a regent of AGAH and a founding member of EUFEMED. He lectures on the AGAH basic human pharmacology course and the University Pompeu Fabra in Barcelona. Dr Täubel is also involved in various other training activities.
Dr. Waring is a licensed physician with clinical experience in internal medicine and a research background in endocrinology and neuropharmacology. He also holds a Master degree in epidemiology. He has more than ten years of industry and consulting experience in clinical drug safety and post-marketing pharmacovigilance, pharmacoepidemiology and pharmaceutical safety risk management. Prior to founding Mark Waring Pharmacovigilance Services in April 2007, he held positions in the drug safety functions of two large, globally operating pharmaceutical companies.
Job Titles:
- President - Elect
- Chemistry, Manufacturing and Control
Job Titles:
- Regulatory Affairs & Compliance
Job Titles:
- Business Economist, Marketing and Sales
Job Titles:
- Chemist, Medical Chemistry
Job Titles:
- Associate Member of the Faculty of Charité Medical School
- Clinical Development, R & D Strategies
Wolf S. Richter founded Pharmtrace in September 2006 to provide expertise and advice to drug developers in the integration and application of medical imaging to the drug development process.
His background encompasses almost 20 years' experience in clinical practice, academic and industrial research. Prior to establishing pharmtrace, he was Head of Clinical Development Diagnostic Imaging / Radiopharmaceuticals and acting Head Digital Image Management in Schering AG, Berlin.
Wolf S. Richter is associate member of the faculty of Charité Medical School. He is specialized and board-certified as a nuclear medicine physician. During his clinical time, he was part the radiological and nuclear medicine services of Charité Medical School. He had the role of a senior physician for cardiovascular imaging. In addition, he established a small animal research lab and successfully studied isolated rat hearts using radiopharmaceutical methods. He published in excess of 40 original articles and more than 100 abstracts in addition to making regular conference contributions as an invited speaker.
Qualifications
MD, Specialisation in Nuclear Medicine; Foreign Medical Graduates Examination in the Medical Sciences (FMGEMS)
Job Titles:
- Toxicology, Medical Writing, Non - Clinical Development, R & D Strategies